MedTrace Logo

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

NCT04000529 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2025-09-30

No results posted yet for this study

Summary

This study was a Phase Ib, multi-center, open-label study of TNO155 in combination with spartalizumab or ribociclib with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.

These two treatment arms enrolled subjects in parallel to characterize the safety, tolerability, PK, PD and preliminary antitumor activity.

The study treatment was administered until the subject experienced unacceptable toxicity, progressive disease, and/or had treatment discontinued at the discretion of the Investigator or the subject, or due to withdrawal of consent.

Conditions

Interventions

DRUG

TNO155

Capsule

DRUG

Spartalizumab

Concentrate for solution for infusion

DRUG

Ribociclib

Capsule and tablet

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-30
Primary Completion
2024-01-15
Completion
2024-01-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • China
  • Germany
  • Hong Kong
  • Japan
  • Singapore
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04000529 on ClinicalTrials.gov